Please provide your email address to receive an email when new articles are posted on . Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared ...
The Tampa Bay Lightning are in the mix for one of the top three spots in the Atlantic Division. It's a neck-and-neck race and the team is currently occupying a wild-card spot. If the Lightning are ...
NCCN upgrades Trodelvy to category 1 preferred first-line therapy for metastatic TNBC with CPS <10 and no germline BRCA1/2 mutation. For PD-L1–positive metastatic TNBC (CPS ≥10), Trodelvy plus ...
For patients diagnosed with locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA), the first line of therapy often represents the most meaningful opportunity to ...
Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Please provide your email address to receive an email when new articles are posted on . Immune checkpoint inhibitor-based combinations are the preferred first-line therapy for metastatic clear cell ...
Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment ...
Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression. The phase 3 RATIONALE-306 study demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results